Labeled for this condition
Medicines for hiv
47 medicines have an FDA label indicated for HIV; 23 are listed from generic labelers and 0 have a presentation in shortage now (FDA files, October 8, 2026).
Which medicines are labeled for hiv?
Each label names the condition in its indications; the record shows the label's words. A list of labeled medicines is not a treatment plan.
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Emtricitabine and tenofovir disoproxil | Truvada | 25 labelers | $0.529 per tablet 200-300 mg tablet | Yes | No current entry | 1 |
| Darunavir | Prezista | 13 labelers | $1.16 per tablet 600 mg tablet | No | No current entry | 0 |
| Lamivudine | Epivir | 14 labelers | $0.489 per tablet 150 mg tablet | Yes | No current entry | 2 |
| Tenofovir disoproxil | Viread | 15 labelers | $0.294 per tablet 300 mg tablet | Yes | No current entry | 0 |
| Maraviroc | Selzentry | 8 labelers | $9.15 per tablet 150 mg tablet | Yes | A presentation being discontinued | 0 |
| Atazanavir | Reyataz | 4 labelers | $2.23 per capsule 300 mg capsule | No | No current entry | 0 |
| Etravirine | Intelence | 5 labelers | $9.94 per tablet 200 mg tablet | No | A presentation being discontinued | 0 |
| Abacavir | Ziagen | 12 labelers | $0.546 per tablet 300 mg tablet | Yes | No current entry | 0 |
| Lamivudine and zidovudine | Combivir | 7 labelers | $0.771 per tablet Lamivudine-zidovudine tablet | Yes | No current entry | 1 |
| Ritonavir | Norvir | 7 labelers | $0.607 per tablet 100 mg tablet | Yes | A presentation being discontinued | 1 |
| Lopinavir and ritonavir | Kaletra | 3 labelers | $4.46 per tablet 200-50 mg tablet | No | A presentation being discontinued | 0 |
| Nevirapine | none listed | 6 labelers | $0.147 per tablet 200 mg tablet | Yes | No current entry | 1 |
| Raltegravir | Isentress | 1 labeler | $34.54 per tablet 400 mg tablet | No | No current entry | 0 |
| Efavirenz | none listed | 5 labelers | $1.28 per tablet 600 mg tablet | No | No current entry | 0 |
| Zidovudine | Retrovir | 3 labelers | $0.464 per tablet 300 mg tablet | Yes | No current entry | 0 |
| Efavirenz and emtricitabine and tenofovir disoproxil | none listed | 7 labelers | $1.12 per tablet 600-200-300 mg tablet | Yes | No current entry | 0 |
| Abacavir and lamivudine | none listed | 6 labelers | $1.48 per unit 600-300 mg | Yes | No current entry | 0 |
| Dolutegravir | Tivicay | none listed | $77.64 per tablet 50 mg tablet | No | No current entry | 3 |
| Emtricitabine | Emtriva | 2 labelers | $12.69 per capsule 200 mg capsule | Yes | A presentation being discontinued | 1 |
| Lenacapavir | Sunlenca, Yeztugo | none listed | n/a | No | No current entry | 0 |
| Bictegravir and emtricitabine and tenofovir alafenamide | Biktarvy | none listed | $136.73 per tablet 50-200-25 mg tablet | Yes | No current entry | 0 |
| Cobicistat and darunavir | Prezcobix | none listed | $79.99 per tablet 800 mg-150 mg tablet | No | No current entry | 0 |
| Rilpivirine | Edurant | 2 labelers | $48.04 per tablet 25 mg tablet | No | No current entry | 0 |
| Cabotegravir | Apretude, Vocabria | none listed | n/a | Yes | No current entry | 0 |
| Cabotegravir and rilpivirine | Cabenuva | none listed | n/a | No | No current entry | 0 |
| Efavirenz and lamivudine and tenofovir disoproxil | Symfi | 1 labeler | n/a | Yes | No current entry | 0 |
| Emtricitabine and rilpivirine and tenofovir disoproxil | Complera | 2 labelers | $114.50 per tablet 200-25-300 mg tablet | Yes | No current entry | 0 |
| Abacavir and dolutegravir and lamivudine | Triumeq | none listed | $130.01 per tablet 600-50-300 mg tablet | Yes | No current entry | 1 |
| Doravirine | Pifeltro | none listed | $60.79 per tablet 100 mg tablet | No | No current entry | 0 |
| Emtricitabine and tenofovir alafenamide | Descovy | none listed | $74.94 per tablet 200-25 mg tablet | Yes | No current entry | 0 |
| Fosamprenavir | none listed | 2 labelers | n/a | No | No current entry | 0 |
| Nelfinavir | Viracept | none listed | n/a | No | No current entry | 1 |
| Abacavir and lamivudine and zidovudine | none listed | 1 labeler | n/a | Yes | No current entry | 0 |
| Atazanavir and cobicistat | Evotaz | none listed | $52.05 per tablet 300 mg-150 mg tablet | No | A presentation being discontinued | 0 |
| Bictegravir and lenacapavir | Bixlenvo | none listed | n/a | No | No current entry | 0 |
| Cobicistat | Tybost | none listed | n/a | No | A presentation being discontinued | 0 |
| Cobicistat, darunavir, emtricitabine and tenofovir alafenamide | Symtuza | none listed | $152.87 per tablet 800-150-200-10 mg tablet | Yes | No current entry | 0 |
| Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide | Genvoya | none listed | $143.35 per tablet Genvoya tablet | Yes | No current entry | 0 |
| Cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil | Stribild | none listed | $150.14 per tablet Stribild tablet | Yes | No current entry | 0 |
| Dolutegravir and lamivudine | Dovato | none listed | $105.22 per tablet 50-300 mg tablet | Yes | No current entry | 0 |
| Dolutegravir and rilpivirine | Juluca | none listed | $121.87 per tablet 50-25 mg tablet | No | No current entry | 0 |
| Doravirine and islatravir | Idvynso | none listed | n/a | No | No current entry | 0 |
| Doravirine and lamivudine and tenofovir disoproxil | Delstrigo | none listed | $93.06 per tablet 100-300-300 mg tablet | Yes | No current entry | 0 |
| Emtricitabine and rilpivirine and tenofovir alafenamide | Odefsey | none listed | $130.49 per tablet Odefsey tablet | Yes | No current entry | 0 |
| Fostemsavir | Rukobia | none listed | $156.84 per tablet 600 mg tablet | No | No current entry | 0 |
| Ibalizumab | Trogarzo | none listed | n/a | No | No current entry | 0 |
| Lamivudine and tenofovir disoproxil | Cimduo | none listed | n/a | Yes | No current entry | 0 |
Source: FDA drug labels (indications) via openFDA; NDC Directory; CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price